Apellis Pharmaceuticals, Inc.
http://www.apellis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Apellis Pharmaceuticals, Inc.
After All The Layoffs, Is Biopharma’s Headcount Still Growing?
While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.
Apellis Slashes Costs To Focus On Troubled Syfovre Launch
The blockbuster-tipped eye therapy Syfovre has hit safety doubts and Apellis is streamlining to give more support to the drug’s global launch.
Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers
Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.
A 3-Month Delay For A Better Label: US FDA User Fee Goal Extensions Are Usually Good News
Pink Sheet analysis finds big jump in the share of novel approvals that received PDUFA extensions, largely driven by clinical and safety data submissions.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice